Lactate  ||| S:0 E:8 ||| NNP
and  ||| S:8 E:12 ||| CC
acid  ||| S:12 E:17 ||| JJ
base  ||| S:17 E:22 ||| NN
as  ||| S:22 E:25 ||| IN
a  ||| S:25 E:27 ||| DT
hemodynamic  ||| S:27 E:39 ||| JJ
monitor  ||| S:39 E:47 ||| NN
and  ||| S:47 E:51 ||| CC
markers  ||| S:51 E:59 ||| NN
of  ||| S:59 E:62 ||| IN
cellular  ||| S:62 E:71 ||| JJ
perfusion  ||| S:71 E:81 ||| NN
:  ||| S:81 E:83 ||| :
The  ||| S:83 E:87 ||| DT
intra-  ||| S:87 E:94 ||| JJ
and  ||| S:94 E:98 ||| CC
postoperative  ||| S:98 E:112 ||| JJ
monitoring  ||| S:112 E:123 ||| NN
of  ||| S:123 E:126 ||| IN
lactate  ||| S:126 E:134 ||| NN
and  ||| S:134 E:138 ||| CC
acid-base  ||| S:138 E:148 ||| NNP
has  ||| S:148 E:152 ||| VBZ
been  ||| S:152 E:157 ||| VBN
advocated  ||| S:157 E:167 ||| VBN
in  ||| S:167 E:170 ||| IN
pediatric  ||| S:170 E:180 ||| JJ
cardiac  ||| S:180 E:188 ||| JJ
critical  ||| S:188 E:197 ||| JJ
care  ||| S:197 E:202 ||| NN
as  ||| S:202 E:205 ||| IN
surrogate  ||| S:205 E:215 ||| JJ
markers  ||| S:215 E:223 ||| NN
of  ||| S:223 E:226 ||| IN
cardiac  ||| S:226 E:234 ||| JJ
output ||| S:234 E:240 ||| NN
,  ||| S:240 E:242 ||| ,
oxygen  ||| S:242 E:249 ||| JJ
delivery ||| S:249 E:257 ||| NN
,  ||| S:257 E:259 ||| ,
and  ||| S:259 E:263 ||| CC
cellular  ||| S:263 E:272 ||| JJ
perfusion ||| S:272 E:281 ||| NN
.  ||| S:281 E:283 ||| .
Many  ||| S:283 E:288 ||| JJ
clinicians  ||| S:288 E:299 ||| JJ
use  ||| S:299 E:303 ||| NN
lactate  ||| S:303 E:311 ||| NNS
and  ||| S:311 E:315 ||| CC
base  ||| S:315 E:320 ||| NN
excess  ||| S:320 E:327 ||| NN
routinely  ||| S:327 E:337 ||| RB
as  ||| S:337 E:340 ||| IN
markers  ||| S:340 E:348 ||| NN
of  ||| S:348 E:351 ||| IN
tissue  ||| S:351 E:358 ||| NN
perfusion  ||| S:358 E:368 ||| NNS
and  ||| S:368 E:372 ||| CC
to  ||| S:372 E:375 ||| TO
assess  ||| S:375 E:382 ||| VB
the  ||| S:382 E:386 ||| DT
effectiveness  ||| S:386 E:400 ||| NN
of  ||| S:400 E:403 ||| IN
their  ||| S:403 E:409 ||| PRP$
intervention ||| S:409 E:421 ||| NN
.  ||| S:421 E:423 ||| .
This  ||| S:423 E:428 ||| DT
review  ||| S:428 E:435 ||| NN
discusses  ||| S:435 E:445 ||| VBD
the  ||| S:445 E:449 ||| DT
strengths  ||| S:449 E:459 ||| NNS
and  ||| S:459 E:463 ||| CC
weaknesses  ||| S:463 E:474 ||| NNS
of  ||| S:474 E:477 ||| IN
using  ||| S:477 E:483 ||| VBG
these  ||| S:483 E:489 ||| DT
measurements  ||| S:489 E:502 ||| NNS
in  ||| S:502 E:505 ||| IN
pediatric  ||| S:505 E:515 ||| JJ
cardiac  ||| S:515 E:523 ||| JJ
critical  ||| S:523 E:532 ||| JJ
care.  ||| S:532 E:538 ||| NN
:  ||| S:538 E:540 ||| :
A  ||| S:540 E:542 ||| DT
search  ||| S:542 E:549 ||| NN
of  ||| S:549 E:552 ||| IN
MEDLINE ||| S:552 E:559 ||| NNP
,  ||| S:559 E:561 ||| ,
EMBASE ||| S:561 E:567 ||| NNP
,  ||| S:567 E:569 ||| ,
PubMed ||| S:569 E:575 ||| NNP
,  ||| S:575 E:577 ||| ,
and  ||| S:577 E:581 ||| CC
the  ||| S:581 E:585 ||| DT
Cochrane  ||| S:585 E:594 ||| NNP
Database  ||| S:594 E:603 ||| NNP
was  ||| S:603 E:607 ||| VBD
conducted  ||| S:607 E:617 ||| VBN
to  ||| S:617 E:620 ||| TO
find  ||| S:620 E:625 ||| VB
controlled  ||| S:625 E:636 ||| VBN
trials  ||| S:636 E:643 ||| NNS
of  ||| S:643 E:646 ||| IN
lactate  ||| S:646 E:654 ||| NN
and  ||| S:654 E:658 ||| CC
base  ||| S:658 E:663 ||| NN
excess ||| S:663 E:669 ||| NN
.  ||| S:669 E:671 ||| .
Adult  ||| S:671 E:677 ||| NN
and  ||| S:677 E:681 ||| CC
pediatric  ||| S:681 E:691 ||| JJ
data  ||| S:691 E:696 ||| NNS
were  ||| S:696 E:701 ||| VBD
considered ||| S:701 E:711 ||| VBN
.  ||| S:711 E:713 ||| .
Guidelines  ||| S:713 E:724 ||| NNS
published  ||| S:724 E:734 ||| VBN
by  ||| S:734 E:737 ||| IN
the  ||| S:737 E:741 ||| DT
Society  ||| S:741 E:749 ||| NNP
of  ||| S:749 E:752 ||| IN
Critical  ||| S:752 E:761 ||| NNP
Care  ||| S:761 E:766 ||| NNP
Medicine ||| S:766 E:774 ||| NNP
,  ||| S:774 E:776 ||| ,
the  ||| S:776 E:780 ||| DT
American  ||| S:780 E:789 ||| NNP
Heart  ||| S:789 E:795 ||| NNP
Association ||| S:795 E:806 ||| NNP
,  ||| S:806 E:808 ||| ,
the  ||| S:808 E:812 ||| DT
American  ||| S:812 E:821 ||| NNP
Academy  ||| S:821 E:829 ||| NNP
of  ||| S:829 E:832 ||| IN
Pediatrics ||| S:832 E:842 ||| NNP
,  ||| S:842 E:844 ||| ,
and  ||| S:844 E:848 ||| CC
the  ||| S:848 E:852 ||| DT
International  ||| S:852 E:866 ||| NNP
Liaison  ||| S:866 E:874 ||| NNP
Committee  ||| S:874 E:884 ||| NNP
on  ||| S:884 E:887 ||| IN
Resuscitation  ||| S:887 E:901 ||| NNP
were  ||| S:901 E:906 ||| VBD
reviewed  ||| S:906 E:915 ||| VBN
including  ||| S:915 E:925 ||| VBG
further  ||| S:925 E:933 ||| JJ
review  ||| S:933 E:940 ||| NN
of  ||| S:940 E:943 ||| IN
references  ||| S:943 E:954 ||| CD
cited.  ||| S:954 E:961 ||| CD
:  ||| S:961 E:963 ||| :
Many  ||| S:963 E:968 ||| JJ
factors  ||| S:968 E:976 ||| NNS
other  ||| S:976 E:982 ||| JJ
than  ||| S:982 E:987 ||| IN
tissue  ||| S:987 E:994 ||| NN
hypoxia  ||| S:994 E:1002 ||| NNS
may  ||| S:1002 E:1006 ||| MD
contribute  ||| S:1006 E:1017 ||| VB
to  ||| S:1017 E:1020 ||| TO
hyperlactemia  ||| S:1020 E:1034 ||| VB
in  ||| S:1034 E:1037 ||| IN
critical  ||| S:1037 E:1046 ||| JJ
illness ||| S:1046 E:1053 ||| NN
.  ||| S:1053 E:1055 ||| .
Although  ||| S:1055 E:1064 ||| IN
the  ||| S:1064 E:1068 ||| DT
presence  ||| S:1068 E:1077 ||| NN
of  ||| S:1077 E:1080 ||| IN
hyperlactemia  ||| S:1080 E:1094 ||| NN
on  ||| S:1094 E:1097 ||| IN
admission  ||| S:1097 E:1107 ||| NN
appears  ||| S:1107 E:1115 ||| VBZ
to  ||| S:1115 E:1118 ||| TO
be  ||| S:1118 E:1121 ||| VB
associated  ||| S:1121 E:1132 ||| VBN
with  ||| S:1132 E:1137 ||| IN
intensive  ||| S:1137 E:1147 ||| JJ
care  ||| S:1147 E:1152 ||| NN
unit  ||| S:1152 E:1157 ||| NN
mortality  ||| S:1157 E:1167 ||| NN
and  ||| S:1167 E:1171 ||| CC
morbidity  ||| S:1171 E:1181 ||| NN
in  ||| S:1181 E:1184 ||| IN
some  ||| S:1184 E:1189 ||| DT
retrospective  ||| S:1189 E:1203 ||| JJ
analyses ||| S:1203 E:1211 ||| NNS
,  ||| S:1211 E:1213 ||| ,
significant  ||| S:1213 E:1225 ||| JJ
overlap  ||| S:1225 E:1233 ||| NN
between  ||| S:1233 E:1241 ||| IN
survivors  ||| S:1241 E:1251 ||| NNS
and  ||| S:1251 E:1255 ||| CC
nonsurvivors  ||| S:1255 E:1268 ||| JJ
means  ||| S:1268 E:1274 ||| NNS
that  ||| S:1274 E:1279 ||| WDT
nonsurvivors  ||| S:1279 E:1292 ||| VBP
cannot  ||| S:1292 E:1299 ||| RB
be  ||| S:1299 E:1302 ||| VB
predicted  ||| S:1302 E:1312 ||| VBN
from  ||| S:1312 E:1317 ||| IN
admission  ||| S:1317 E:1327 ||| NN
lactate  ||| S:1327 E:1335 ||| NN
measurement ||| S:1335 E:1346 ||| NN
.  ||| S:1346 E:1348 ||| .
Persistently  ||| S:1348 E:1361 ||| FW
elevated  ||| S:1361 E:1370 ||| FW
postoperative  ||| S:1370 E:1384 ||| FW
lactate  ||| S:1384 E:1392 ||| FW
is  ||| S:1392 E:1395 ||| VBZ
associated  ||| S:1395 E:1406 ||| VBN
with  ||| S:1406 E:1411 ||| IN
increased  ||| S:1411 E:1421 ||| JJ
morbidity  ||| S:1421 E:1431 ||| NN
and  ||| S:1431 E:1435 ||| CC
mortality  ||| S:1435 E:1445 ||| NN
in  ||| S:1445 E:1448 ||| IN
the  ||| S:1448 E:1452 ||| DT
pediatric  ||| S:1452 E:1462 ||| JJ
cardiac  ||| S:1462 E:1470 ||| JJ
population ||| S:1470 E:1480 ||| NN
.  ||| S:1480 E:1482 ||| .
To  ||| S:1482 E:1485 ||| TO
date  ||| S:1485 E:1490 ||| VB
there  ||| S:1490 E:1496 ||| EX
is  ||| S:1496 E:1499 ||| VBZ
no  ||| S:1499 E:1502 ||| DT
randomized  ||| S:1502 E:1513 ||| JJ
control  ||| S:1513 E:1521 ||| NN
trial  ||| S:1521 E:1527 ||| NN
of  ||| S:1527 E:1530 ||| IN
goal-directed  ||| S:1530 E:1544 ||| JJ
therapy  ||| S:1544 E:1552 ||| NN
in  ||| S:1552 E:1555 ||| IN
adult  ||| S:1555 E:1561 ||| NN
or  ||| S:1561 E:1564 ||| CC
pediatric  ||| S:1564 E:1574 ||| JJ
cardiac  ||| S:1574 E:1582 ||| JJ
care  ||| S:1582 E:1587 ||| NN
that  ||| S:1587 E:1592 ||| WDT
includes  ||| S:1592 E:1601 ||| VBZ
normalization  ||| S:1601 E:1615 ||| VBN
of  ||| S:1615 E:1618 ||| IN
lactate  ||| S:1618 E:1626 ||| NN
as  ||| S:1626 E:1629 ||| IN
a  ||| S:1629 E:1631 ||| DT
target ||| S:1631 E:1637 ||| NN
.  ||| S:1637 E:1639 ||| .
Overall  ||| S:1639 E:1647 ||| JJ
equivalent  ||| S:1647 E:1658 ||| JJ
time  ||| S:1658 E:1663 ||| NN
measurements  ||| S:1663 E:1676 ||| NNS
of  ||| S:1676 E:1679 ||| IN
base  ||| S:1679 E:1684 ||| NN
excess ||| S:1684 E:1690 ||| NN
,  ||| S:1690 E:1692 ||| ,
anion  ||| S:1692 E:1698 ||| JJ
gap ||| S:1698 E:1701 ||| NN
,  ||| S:1701 E:1703 ||| ,
and  ||| S:1703 E:1707 ||| CC
pH  ||| S:1707 E:1710 ||| NNS
have  ||| S:1710 E:1715 ||| VBP
a  ||| S:1715 E:1717 ||| DT
low  ||| S:1717 E:1721 ||| JJ
predictive  ||| S:1721 E:1732 ||| JJ
value  ||| S:1732 E:1738 ||| NN
for  ||| S:1738 E:1742 ||| IN
morbidity  ||| S:1742 E:1752 ||| NN
and  ||| S:1752 E:1756 ||| CC
mortality  ||| S:1756 E:1766 ||| NN
in  ||| S:1766 E:1769 ||| IN
children  ||| S:1769 E:1778 ||| NNS
after  ||| S:1778 E:1784 ||| IN
cardiac  ||| S:1784 E:1792 ||| JJ
surgery ||| S:1792 E:1799 ||| NN
.  ||| S:1799 E:1801 ||| .
Lactate  ||| S:1801 E:1809 ||| NNP
is  ||| S:1809 E:1812 ||| VBZ
one  ||| S:1812 E:1816 ||| CD
of  ||| S:1816 E:1819 ||| IN
a  ||| S:1819 E:1821 ||| DT
cluster  ||| S:1821 E:1829 ||| NN
of  ||| S:1829 E:1832 ||| IN
markers  ||| S:1832 E:1840 ||| NN
of  ||| S:1840 E:1843 ||| IN
cellular  ||| S:1843 E:1852 ||| JJ
perfusion  ||| S:1852 E:1862 ||| NN
and  ||| S:1862 E:1866 ||| CC
oxygen  ||| S:1866 E:1873 ||| JJ
delivery ||| S:1873 E:1881 ||| NN
.  ||| S:1881 E:1883 ||| .
Alone ||| S:1883 E:1888 ||| RB
,  ||| S:1888 E:1890 ||| ,
as  ||| S:1890 E:1893 ||| IN
a  ||| S:1893 E:1895 ||| DT
single  ||| S:1895 E:1902 ||| JJ
measurement ||| S:1902 E:1913 ||| NN
,  ||| S:1913 E:1915 ||| ,
it  ||| S:1915 E:1918 ||| PRP
has  ||| S:1918 E:1922 ||| VBZ
minimal  ||| S:1922 E:1930 ||| JJ
predictive  ||| S:1930 E:1941 ||| JJ
value  ||| S:1941 E:1947 ||| NN
and  ||| S:1947 E:1951 ||| CC
is  ||| S:1951 E:1954 ||| VBZ
nondiscriminatory  ||| S:1954 E:1972 ||| VBN
for  ||| S:1972 E:1976 ||| IN
survival ||| S:1976 E:1984 ||| NN
.  ||| S:1984 E:1986 ||| .
